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Abstract
Objectives:  A  burn  patient  is  a  challenge  for  any  anesthesiologist,  undergoing  several  surgeries
during admission,  and  requiring  general  anesthesia  and  muscle  relaxation  most  of  the  times.
The victim  may  have  respiratory  system  impairment  and  a  response  to  muscle  relaxants  that
differs from  the  healthy  patient,  thus  proper  monitoring  and  reversal  is  crucial.  We  analyzed
sugammadex  effectiveness  and  safety  in  this  population.
Materials  and  methods:  It  was  a  prospectively  descriptive  study,  including  4  patients,  and  all
of them  were  considered  major  burn  patients,  who  underwent  escharotomy  with  general  anes-
thesia and  neuromuscular  relaxation.  The  main  variable  was  the  time  for  recovery  of  a  TOF
higher than  0.9  after  the  administration  of  sugammadex  before  extubation.
Results:  Mean  time  of  recovery  from  a  TOF  ratio  higher  than  0.9  following  the  administration
of Sugammadex  was  of  4.95  min  95%  CI  (3.25--6.64,  p  =  .53).
Conclusions:  The  reversion  of  neuromuscular  relaxation  with  sugammadex  appears  to  be  effec-
tive and  safe  in  the  burn  patient.  More  analytical,  comparative  studies  of  larger  populations
would be  necessary  to  conﬁrm  these  data.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
PALAVRAS-CHAVE
Sugammadex;
Gama-Ciclodextrinas;
Uso  de  sugamadex  no  paciente  queimado:  estudo  descritivo
Resumo
Queimaduras; Objetivos:  O  paciente  queimado  representa  um  desaﬁo  para  o  anestesiologista,  pois  submete-
úrgicas  durante  sua  hospitalizac¸ão,  necessitando  de  anestesia  geral
 maior  parte  delas.  Apresenta  sistema  respiratório  comprometido
tes  musculares  que  difere  do  paciente  sadio;  portanto,  um  moni-
ão  tornam-se  imprescindíveis.  Avaliamos  a  eﬁcácia  e  seguranc¸a doRocurônio;
Bloqueio
neuromuscular;
Neostigmina
se a  várias  intervenc¸ões  cir
e relaxamento  muscular  na
e uma  resposta  aos  relaxan
toramento  correto  e  revers
sugamadex  nesta  populac¸ão.
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Material  e  métodos:  Estudo  descritivo  com  caráter  prospectivo  que  inclui  quatro  pacientes,
todos eles  considerados  grandes  queimados,  submetidos  a  escarectomia  com  anestesia  geral  e
relaxamento  neuromuscular.  Como  variável  principal  tomou-se  o  tempo  de  recuperac¸ão  de  TOF
superior a  0,9  após  a  administrac¸ão  de  sugamadex  antes  de  extubac¸ão.
Resultados:  O  tempo  médio  de  recuperac¸ão  de  uma  razão  TOF  superior  a  0,9  após  a
administrac¸ão de  sugamadex  foi  de  4,95  min  (IC95%  3,25-6,64;  p  =  0,53).
Conclusões:  A  reversão  do  relaxamento  neuromuscular  com  sugamadex  parece  ser  eﬁcaz  e
segura no  paciente  queimado.  Seriam  necessários  mais  estudos  analíticos,  comparativos  e  de
maior populac¸ão  para  conﬁrmar  esses  dados.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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DIntroduction
Burns  are  tissue  injuries  produced  by  skin  aggression  from
any  source  of  energy.  The  severity  criteria  would  be  involve-
ment  of  more  than  25%  of  total  body  surface,  burns  that
follow  inhalation  syndrome,  involvement  of  face,  eyes,
hands,  feet  and  perineum.1 Mortality  of  major  burn  patients
is  approximately  13.9%.2,3 In  our  unit,  174  patients  were
attended  in  the  year  of  2012.  These  patients  underwent  sev-
eral  surgical  interventions  during  their  stay  in  the  hospital,
with  most  of  them  under  general  anesthesia,  orotracheal
intubation,  and  neuromuscular  relaxation.
Sugammadex  is  a  modiﬁed  cyclodextrin  used  for  reversion
of  rocuronium-  and  vecuronium-induced  nondepolarizing
muscle  block.4,5 The  dose  of  sugammadex  varies  depend-
ing  on  the  level  of  muscle  relaxation,  with  mean  time  for
recovery  of  a  TOF  ratio  higher  than  0.9  of  3  min.  (min).6,7
Several  studies  demonstrated  the  superiority  of  this  drug
compared  to  neostigmine8--10 regarding  safety  and  time  for
recovery.  It  was  successfully  used  in  the  obese  patient,  in
the  elderly,  and  also  in  children  older  than  two  years.11
However,  its  use  in  the  major  burn  patient  had  not  been
studied.  The  main  objective  of  this  work  was  to  analyze  the
efﬁcacy  of  sugammadex  in  this  patient  proﬁle  in  whom  the
metabolic-hemodynamic  changes  may  alter  its  pharmacol-
ogy  and  in  whom,  due  to  respiratory  system  involvement  (if
constant),  an  appropriate  reversal  of  neuromuscular  block-
ers  is  crucial.  Secondary  objectives  are  the  measurement  of
neuromuscular  relaxation  recovery  time  after  its  adminis-
tration,  the  comparison  of  these  results  with  those  existing
in  the  literature  in  other  types  of  patients,  report  of  the
emergence  of  adverse  effects  related  to  its  administration,
and  report  of  main  anesthetic  considerations  of  major  burn
patient.
Materials and methods
A  prospective  descriptive  study  of  four  cases  was  conducted
over  two  months.  Inclusion  criteria  were  as  follows:  major
burn  patient  who  underwent  escharotomy  under  general
anesthesia  and  orotracheal  intubation.  Exclusion  criteria
were:  allergy  to  sugammadex,  severe  renal  impairment
T
i
tcreatinine  clearance  below  30  mL  min−1,  intraoperative
emodynamic  instability  requiring  administration  of  amines,
r  the  need  for  blood  transfusions.  All  patients  were
onitored  with  electrocardiogram,  oxygen  saturation,  non-
nvasive  blood  pressure  and  monitoring  of  neuromuscular
lockade  by  accelerometry  (TOF  watch).  Induction  was  con-
ucted  with  propofol  (2.5  mg  kg−1),  fentanyl  (2  g kg−1)  and
ocuronium  (0.6  mg  kg−1).  Maintenance  was  performed  with
evoﬂurane  at  1  CAM,  with  the  administration  of  a  booster
ose  of  relaxant  (30%  the  initial  dose)  on  those  who  showed
ecovery  from  block  (emergence  of  2  responses  in  TOF).  At
he  end  of  the  surgery,  and  before  extubation,  sugammadex
as  administered  in  all  cases,  with  the  dose  according  to
he  level  neuromuscular  block  (deep  block  4  mg  kg−1,  moder-
te  block  2  mg  kg−1,  recovery  phase  with  4  responses  to  TOF
atio  1  mg  kg−1).  The  patients  were  extubated  after  recovery
f  TOF  higher  than  0.9.  The  variable  considered  was  time
n  minutes  since  the  administration  of  sugammadex  until
ecovery  of  TOF  higher  than  0.9.  All  the  time  we  followed  the
thical  standards  of  the  human  experimentation  committee
f  our  center.  For  data  analysis,  we  used  the  software  IBM
PSS  Statistics  22.0.
esults
our  patients  with  ages  between  69  and  76  years  were
ncluded.  The  clinical  characteristics  of  the  patients  are
ummarized  in  Table  1,  and  Fig.  1  shows  one  of  the  patients
ncluded  in  the  study.  The  average  percentage  of  body  sur-
ace  area  burned  was  17.25%.  Two  of  the  patients  received
 booster  dose  of  rocuronium  (20  and  25  mg  respectively).
he  average  recovery  time  from  a  TOF  ratio  greater  than
.9  after  sugammadex  administration  before  extubation
as  4.95  min  with  a  95%  conﬁdence  interval  of  3.25--6.64
p  =  0.53).  The  median  of  the  same  variable  was  of  4.65  min.
ypical  deviation  was  of  1.06.
iscussionhe  involvement  of  the  respiratory  system  is  almost  constant
n  major  burn  patients;  there  is  vasodilation  that  contributes
o  respiratory  mucosa  edema  and  increased  permeability  of
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Table  1  Patients’  clinical  characteristics.
Case  Patient  1  Patient  2  Patient  3  Patient  4
Age  (years) 76  77  69  72
Gender Female  Female  Male  Female
Comorbidity  Hypertension,
dyslipidemia,
depression
Hypertension,
osteoporosis
Dementia,
blindness
Hypertension
Burn  body  surface  (%)  18  12  25  14
Time for  recovery  of  TOF  higher  than  0.9  min  4.2  5.1  4.1  6.4
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RBooster dose  of  rocuronium  (mg)  No  
ung  capillaries,12 and  therefore  the  control  of  lung  func-
ion  shall  be  our  priority.  In  severe  burn  patients,  there  is
 proliferation  of  immature  acetylcholine  receptors  on  both
euromuscular  plate  and  extra-synaptic  sites.  This  leads  to
n  increased  sensitivity  to  depolarizing  relaxants  (succinyl-
holine),  with  risk  of  severe  hyperkalemia  and  a  resistance
o  non-depolarizing  neuromuscular  blocking  agents,  increas-
ng  instauration  latency,  and  reducing  the  time  of  action13;
his,  along  with  a  possible  renal  impairment  may  result  in
ts  accumulation  after  readministration,  with  risk  of  residual
urarization.  The  use  of  muscle  relaxation  reversion  agents,
nd  its  monitoring  are  effective  measures  to  prevent  pare-
is;  the  presence  of  TOF  ratio  greater  than  0.9  is  considered
afe  to  perform  extubation.14 The  anticholinesterase  drugs
neostigmine,  edrophonium)  are  routinely  used  for  reversal
f  neuromuscular  relaxation  in  burn  patients;  these  drugs
roduce  adverse  effects  derived  from  the  increase  of  acetyl-
holine  and  its  interaction  with  muscarinic  receptors  out  of
ntersynaptic  site.  The  average  time  to  reach  a  TOF  value
igher  than  0.9  after  the  reappearance  of  the  2  responses
o  TOF  is  of  18.5  min  after  neostigmine  administration.15 It  is
hown  ineffective  to  reverse  deep  block.  The  emergence  of
ugammadex  assumed  to  be  a  revolution  in  this  regard,  but
t  has  not  been  studied  in  burn  patients,  with  a  more  rapid
nd  predictable  beginning  of  action  being  demonstrated  in
everal  studies,  compared  to  neostigmine,  and  being  effec-
ive  in  a  deep  block.8--11 In  our  study  the  mean  time  to
ecovery  of  TOF  ratio  greater  than  0.9  after  sugammadex
Figure  1  A  patient  included  in  the  study.
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dministration  was  4.95  min,  time  that  is  lower  than  that
f  neostigmine  in  other  populations.  None  of  the  patients
howed  complications  related  to  the  administration  of  sug-
mmadex.  These  data,  although  preliminary,  have  shown
hat  sugammadex  can  be  used  in  these  patients,  with  recov-
ry  times  for  muscle  activity  similar  to  that  in  other  types
f  patients.  More  prospective  comparative  analytical  stud-
es  with  more  patients  are  necessary  to  conﬁrm  the  results
f  this  work.
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